Longevity & AgingLinnaeus Drug LNS8801 Enters Elite NIA Lifespan Testing Program
Linnaeus Therapeutics has announced that its lead drug candidate, LNS8801, has been selected for the National Institute on Aging's Interventions Testing Program — one of the most demanding longevity research initiatives in the world. The program tests interventions simultaneously at three independent labs using identical protocols and genetically diverse mice, making it far harder to game than typical preclinical studies. LNS8801 targets GPER, a receptor involved in estrogen signaling, and will now enter full lifespan testing as part of the 2026 cohort. Separately, Linnaeus received up to $22 million from ARPA-H's PROSPR program to study whether the drug can preserve healthspan — the ability to move, think, and function well — not just add years to life.
